Home
This site is intended for healthcare professionals
Sign upLog in

Key Clinical Summary: Incorporating GLP‑1 Receptor Agonists Into Treatment Plans for T2D and CKD

This is a micro-learning module summary of the session by Dr. Sankar Navaneethan which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent educational grant from Novo Nordisk. This education program is only available to healthcare professionals in the USA.

Introduction

This summary explores contemporary evidence supporting GLP‑1 receptor agonists (GLP‑1 RAs) for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), outlining mechanisms of action, clinical trial data, and current guideline recommendations. It reviews key outcomes from major studies including LEADER and FLOW‑CKD and practical considerations for integrating GLP‑1 RAs into therapeutic algorithms for T2D‑associated CKD.

Mechanisms of Action and Kidney‑Relevant Effects

  • GLP‑1 RAs act on receptors throughout the body, enhancing glucose‑dependent insulin secretion and reducing glucagon levels.
  • Slowed gastric emptying and central appetite regulation contribute to clinically meaningful weight loss.
  • Indirect renal benefits arise from improvements in obesity, hypertension, dyslipidemia, and hyperglycemia, each a modifiable risk factor for CKD progression.
  • Direct renal effects described in emerging research include:
    • Reduced glomerular hyperfiltration
    • Improved renal oxygenation
    • Lower inflammatory burden within the glomerulus
    • Reduced lipotoxicity
    • Improved sodium handling
  • Ongoing studies using imaging and biopsy‑based assessments aim to further characterize these direct mechanisms.

Evidence Supporting GLP‑1 RAs in CKD

LEADER Trial (Liraglutide)

  • Included 9,340 adults with T2D and high cardiovascular risk, randomized to liraglutide or placebo.
  • Renal outcomes assessed as a prespecified secondary composite of new‑onset persistent macroalbuminuria, doubling of serum creatinine with estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m², end‑stage renal disease, or death due to renal disease.
  • Key results:
    • 22% reduction in the composite renal outcome
    • 26% reduction in new‑onset persistent macroalbuminuria
    • No significant differences in doubling of serum creatinine, need for renal‑replacement therapy, or renal death
    • Slower progression of albuminuria and modestly slower eGFR decline over time
  • Although not powered for kidney failure endpoints, the trial provided the first large‑scale evidence that GLP‑1 RAs may slow the development and progression of diabetic kidney disease.

FLOW‑CKD Trial (Semaglutide 1 mg Weekly)

  • Included 3,533 participants with T2D and CKD defined by eGFR 25–75 mL/min/1.73 m² and albuminuria thresholds between 100–5000 mg/g.
  • Participants were randomized to subcutaneous semaglutide 1.0 mg weekly or placebo.
  • Primary composite outcome encompassed kidney failure, ≥50% eGFR decline, or death from kidney‑related or cardiovascular causes.
  • Key results:
    • 24% reduction in first major kidney disease event
    • 21% reduction in kidney‑specific component outcomes
    • ~20% reduction in major cardiovascular events and in all‑cause mortality
  • Additional metabolic benefits included:
    • Mean weight reduction of ~4 kg
    • HbA1c reduction of ~0.8%
    • Modest systolic blood pressure reduction
  • Gastrointestinal (GI) adverse events were the primary reason for discontinuation, consistent with known class effects.

Meta‑analyses and Broader Evidence

  • Across 12 randomized trials including ~18,000 individuals with eGFR <60 mL/min/1.73 m², GLP‑1 RAs were associated with:
    • 15% reduction in kidney adverse events
    • 14% reduction in cardiovascular outcomes
    • 23% reduction in all‑cause mortality
  • In individuals without CKD at baseline, GLP‑1 RAs reduced incident microalbuminuria by 24%, suggesting preventive potential.

Safety and Tolerability

  • GI symptoms (nausea, diarrhea, constipation) are the most common adverse events.
    • Rates of GI events in CKD populations mirror those observed in general T2D populations
  • No increased risk of pancreatitis, biliary disease, or medullary thyroid cancer.

Guideline Recommendations

  • KDIGO 2022 (under revision): Recommends long‑acting GLP‑1 RAs for patients with T2D and CKD who have not met glycemic targets despite metformin and sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy.
  • ADA Standards of Care 2026: GLP‑1 RAs are positioned as a core therapeutic option after lifestyle modification, renin-angiotensin system (RAS) blockade, and SGLT2 inhibitors.
    • Preferred when additional glycemic control is needed, weight loss is a priority and/or liver disease is present
    • Can be used across CKD stages; most agents require no dose adjustment, except exenatide, which should be avoided when CrCl is <30 mL/min

Clinical Integration and Therapeutic Algorithm

  • In patients with T2D, CKD (eGFR ~45 mL/min/1.73 m²), and persistent albuminuria already treated with metformin, an SGLT2 inhibitor, and maximally tolerated RAS blockade, the next guideline‑supported step is the addition of a long‑acting GLP‑1 RA.
  • GLP‑1 RAs provide:
    • Additional HbA1c lowering
    • Weight reduction
    • Independent reductions in albuminuria
    • Cardiovascular and renal protection beyond glycemic effects
  • They complement, rather than replace, SGLT2 inhibitors and RAS blockade and fit naturally into a layered, multimodal approach to slowing CKD progression.

Conclusions
GLP‑1 RAs have emerged as a key therapeutic class for patients with T2D and CKD, offering metabolic, cardiovascular, and renal benefits supported by robust clinical trial evidence. Their mechanisms include both indirect metabolic improvements and direct renal effects. Current KDIGO and ADA guidelines endorse long‑acting GLP‑1 RAs when glycemic targets remain unmet despite metformin and SGLT2 inhibitor therapy, or when additional weight loss or cardiometabolic benefit is desired. Evidence also suggests potential preventive effects on albuminuria. Collectively, GLP‑1 RAs represent an essential component of modern, guideline‑aligned care for T2D‑associated CKD.